Citius Oncology has partnered with technology company Verix to advance the commercial launch of its novel immunotherapy Lymphir. 

Lymphir is used for the treatment of adult patients with elapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The treatment was previously approved by the US Food and Drug Administration (FDA) in August 2024.   

The partnership between Citius, the oncology subsidiary of Citius Pharmaceuticals, and Verix will use artificial intelligence and a machine-learning platform to support the salesforce targeting and engagement for Lymphir. 

“We are committed to leveraging leading-edge technologies to maximise the commercial impact of Lymphir and look forward to using [Verix’s] innovative AI platform to amplify the precision and impact of our experienced commercial and marketing teams,” said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma.  

“Through our collaboration with Verix, we are able to enhance our salesforce’s experience with the ability to identify key treatment patterns, personalise provider engagement, and allocate commercial resources efficiently.  

“With Lymphir poised to become a meaningful new option for patients with relapsed or refractory CTCL, it’s critical that our commercial organisation has precision tools that accelerate physician engagement and product uptake. This data-driven approach positions us to execute a focused and impactful launch while maintaining a lean infrastructure.” 

Citius Oncology believes that integrating Verix’s AI capabilities will not only enable faster market penetration but also deliver durable advantages as the company builds its oncology franchise.  

“The Tovana platform is designed to empower life sciences commercial organisations to move from retrospective analysis to real-time action,” added Doron Aspitz, CEO of Verix. 

“With Citius Oncology, we see a strong alignment in using AI to bridge data with execution, and we are excited to help deliver meaningful insights that can accelerate the reach of an innovative therapy like Lymphir.” 

Bruno Quinney, Content Team, DDW